# EDGAR Filing Document

**Accession Number:** 0001178879
**File Stem:** 0001104659-25-056879
**Filing Date:** 2025-6
**Character Count:** 113947
**Document Hash:** 60fdefac1ba7b70c1da2fc88d8a3a42f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-056879.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001104659-25-056879

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**EFFECTIVENESS DATE**: 20250605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMICUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001178879
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 200422823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287807
- **FILM NUMBER:** 251027762

**BUSINESS ADDRESS:**
- **STREET 1:** 47 HULFISH STREET
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08542
- **BUSINESS PHONE:** (609) 662-2000

**MAIL ADDRESS:**
- **STREET 1:** 47 HULFISH STREET
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08542

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMICUS THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20020729

**As filed with the Securities and Exchange Commission on June 5, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

REGISTRATION STATEMENT<br> UNDER THE SECURITIES ACT OF 1933

**AMICUS THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **71-0869350** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |

---

**47 Hulfish Street**

**Princeton, New Jersey 08542**

(Address of Principal Executive Offices) (Zip Code)

**AMICUS THERAPEUTICS, INC.**

**AMICUS THERAPEUTICS, INC.**

**AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN**

**AMICUS THERAPEUTICS, INC.**

**2025 EQUITY INCENTIVE PLAN**

(Full title of the plan)

**Bradley L. Campbell**

**Chief Executive Officer**

**Amicus Therapeutics, Inc.**

**47 Hulfish Street**

**Princeton, New Jersey 08542**

(Name and address of Agent for Service)

**(609) 662-2000**

(Telephone Number of Agent for Service)

**Copy to:**

**Scott R. Jones, Esquire**

**Troutman Pepper Locke LLP**

**400 Berwyn Park** 

**899 Cassatt Road** 

**Berwyn, Pennsylvania 19312-1183**

**(610)640-7800**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ⌧ Accelerated filer ◻ <br> Non-accelerated filer ◻ Smaller reporting company ◻ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purposes of registering (i) 17,476,463 shares of the common stock of Amicus Therapeutics, Inc. (the "Company), par value $0.01 per share, to be issued pursuant to the Amicus Therapeutics, Inc. 2025 Equity Incentive Plan ("2025 Plan"), as approved by the Company's stockholders at the 2025 Annual Meeting of Stockholders on June 5, 2025 and (ii) an additional 7,783,410 shares of Common Stock that will be issuable pursuant to options, restricted stock units and performance restricted stock units outstanding under the Company's Amended and Restated 2007 Equity Incentive Plan ("2007 Plan") for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective.

Pursuant to General Instruction E to Form S-8, with respect to the 2007 Plan, the contents of the Registration Statements on Form S-8 (File Nos. 333-145305, 333-157219, 333-174900, 333-233153, 333-243779, 333-257289, 333-265531, 333-272621 and 333-280055) filed with the Securities and Exchange Commission (the "Commission") on [August 10, 2007](https://www.sec.gov/Archives/edgar/data/1178879/000095012307011217/y37940sv8.htm), [February 10, 2009](https://www.sec.gov/Archives/edgar/data/1178879/000089322009000251/w72683sv8.htm), [June 15, 2011](https://www.sec.gov/Archives/edgar/data/1178879/000095012311059118/c18760sv8.htm), [August 8, 2019](https://www.sec.gov/Archives/edgar/data/1178879/000110465919044956/a19-16819_1s8.htm), [August 11, 2020](https://www.sec.gov/Archives/edgar/data/1178879/000110465920092862/tm2026897d1_s8.htm), [June 22, 2021](https://www.sec.gov/Archives/edgar/data/1178879/000110465921084168/tm2119601d2_s8.htm), [June 10, 2022](https://www.sec.gov/Archives/edgar/data/1178879/000110465922070177/tm2218031d2_s8.htm), [June 13, 2023](https://www.sec.gov/Archives/edgar/data/1178879/000110465923070869/tm2318498d1_s8.htm) and [June 7, 2024](https://www.sec.gov/Archives/edgar/data/1178879/000110465924069701/tm2416641d1_s8.htm), respectively, are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. With respect to the 2007 Plan, only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Item 1 and Item 2 of Part I of the Registration Statement on Form S-8 (this "Registration Statement") is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the 2025 Plan covered by this Registration Statement as required by Rule 428(b)(1).

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed with the Securities and Exchange Commission (the "Commission") by Amicus Therapeutic's Inc. (the "Registrant") pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated herein by reference, to the extent that such documents are considered filed with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 19, 2025;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Information specifically incorporated by reference into the [Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm) from its Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 24,
2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) [The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 1, 2025; and](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000117887925000006/fold-20250331.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Registrant's Current Reports on Form 8-K filed with the Commission on [February 21, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465925016127/tm257266d2_8k.htm) , [May 1, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465925043008/tm2513759d2_8k.htm) and [June 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000110465925056821/tm2517200d1_8k.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The description of the Registrant's common stock, par value $0.01 per share (the "Common Stock")
contained in [Exhibit 4.3 to its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 19, 2025](https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-descriptionofsecuriti.htm) , which updates the description of the Registrant's Common Stock contained in the Registrant's registration statement
on [Form 8-A filed with the Commission on May 23, 2007](https://www.sec.gov/Archives/edgar/data/1178879/000095012307007844/y32191ae8va12b.htm) , and including any other amendments or reports filed for the purpose of further
updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all of such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents, to the extent such documents are considered filed with the Commission.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors and certain officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or applicable officer, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, obtained an improper personal benefit, with respect to directors, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or, with respect to officers, an action is by or in the right of the corporation. The Registrant's restated certificate of incorporation provides that no director or applicable officer of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.

The Registrant's restated certificate of incorporation provides that the Registrant will, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law and the Registrant's by-laws (each as amended from time to time), indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was serving, or has agreed to serve, at the request of the Registrant, as a director, officer, partner, or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan (all such persons being referred to hereafter as an "Indemnitee"), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by, or on behalf of, the Indemnitee in connection with such action, suit or proceeding and any appeal therefrom. Such indemnification may include payment by the Registrant of expenses in defending an action or proceeding in advance of the final disposition of such action or proceeding upon receipt of an undertaking by the Indemnitee (such undertaking acceptable by the Registrant without reference to the financial ability of the Indemnitee) to repay such payment if it is ultimately determined that the Indemnitee is not entitled to indemnification under the Registrant's restated certificate of incorporation; however, the Registrant will not indemnify any person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person, unless such initiation was approved by the Registrant's board of directors. Also, the indemnification rights provided in the Registrant's restated certificate of incorporation (i) are not exclusive of any other rights to which those indemnified may be entitled under any law, agreement or vote of stockholders or disinterested directors or otherwise, and (ii) will inure to the benefit of the heirs, executors and administrators of such persons. The Registrant may, to the extent authorized from time to time by its board of directors, grant indemnification rights to other employees or agents of the Registrant or other persons serving the Registrant and such rights may be equivalent to, or greater or less than, those set forth in the Registrant's restated certificate of incorporation.

The Registrant has entered into indemnification agreements with each of its directors. These agreements, among other things, require the Registrant to indemnify each director to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys' fees, judgments, fines and settlement amounts incurred by the director in any action or proceeding, including any action or proceeding by or in right of the Registrant, arising out of the person's services as a director.

The Registrant maintains a general liability insurance policy that covers certain liabilities of the Registrant's directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. In any underwriting agreement that the Registrant enters into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, the Registrant, its directors, its officers and persons who control the Registrant within the meaning of the Securities Act, against certain liabilities.

**Item 7. Exemption From Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description</u> |
| [4.1](https://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm) | [Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K filed on February 28, 2012)](https://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm) | [Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 10, 2015)](https://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm) | [Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 8, 2018)](https://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1178879/000110465923070827/tm2318498d2_ex3-1.htm) | [Certificate of Amendment to the Registrant's Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on June 13, 2023)](https://www.sec.gov/Archives/edgar/data/1178879/000110465923070827/tm2318498d2_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1178879/000117887923000013/exhibit32_secondamendedand.htm) | [Second Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q filed on August 8, 2023)](https://www.sec.gov/Archives/edgar/data/1178879/000117887923000013/exhibit32_secondamendedand.htm) |
| [5.1\*](tm2517141d1_ex5-1.htm) | [Opinion of Troutman Pepper Locke LLP](tm2517141d1_ex5-1.htm) |
| [23.1\*](tm2517141d1_ex23-1.htm) | [Consent of Ernst & Young LLP](tm2517141d1_ex23-1.htm) |
| [23.2\*](tm2517141d1_ex5-1.htm) | [Consent of Troutman Pepper Locke LLP (included in Exhibit 5.1)](tm2517141d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Powers of Attorney (included in signature page)](#a_001) |
| [99.1](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000114036125015479/ny20044252x1_def14a.htm) | [Amended and Restated 2007 Equity Incentive Plan (incorporated by reference to Exhibit A to the Registrant's Definitive Proxy Statement on Schedule 14A filed on April 24, 2024)](https://www.sec.gov/ix?doc=/Archives/edgar/data/1178879/000114036125015479/ny20044252x1_def14a.htm) |
| [99.2\*](tm2517141d1_ex99-2.htm) | [Amicus Therapeutics 2025 Equity Incentive Plan](tm2517141d1_ex99-2.htm) |
| [107.1\*](tm2517141d1_ex-filingfees.htm) | [Filing Fee Table](tm2517141d1_ex-filingfees.htm) |
|  | \* Filed herewith. |

---

**Item 9. Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Princeton, State of New Jersey, on the 5th day of June, 2025.

---

| | |
|:---|:---|
| **AMICUS THERAPEUTICS, INC.** | **AMICUS THERAPEUTICS, INC.** |
| By: | /s/ Bradley L. Campbell |
| Name: | Bradley L. Campbell |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

We, the undersigned officers and directors of Amicus Therapeutics, Inc., hereby severally constitute and appoint Bradley L. Campbell, Simon Harford and Ellen S. Rosenberg, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Amicus Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said Registration Statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ Bradley L. Campbell | President, Chief Executive Officer and Director<br> (Principal Executive Officer) | June 5, 2025 |
| Bradley L. Campbell |  |  |
| /s/ Simon Harford | Chief Financial Officer<br> (Principal Financial Officer) | June 5, 2025 |
| Simon Harford |  |  |
| /s/ Samantha L. Prout | Chief Accounting Officer and Controller<br> (Principal Accounting Officer) | June 5, 2025 |
| Samantha L. Prout |  |  |
| /s/ Michael G. Raab | Chairman of the Board | June 5, 2025 |
| Michael G. Raab |  |  |
| /s/ Lynn D. Bleil | Director | June 5, 2025 |
| Lynn D. Bleil |  |  |
| /s/ Michael A. Kelly | Director | June 5, 2025 |
| Michael A. Kelly |  |  |
| /s/ Margaret G. McGlynn | Director | June 5, 2025 |
| Margaret G. McGlynn |  |  |
| /s/ Eiry W. Roberts, M.D. | Director | June 5, 2025 |
| Eiry W. Roberts, M.D. |  |  |
| /s/ Glenn P. Sblendorio | Director | June 5, 2025 |
| Glenn P. Sblendorio |  |  |
| /s/ Craig A. Wheeler | Director | June 5, 2025 |
| Craig A. Wheeler |  |  |
| /s/ Burke W. Whitman | Director | June 5, 2025 |
| Burke W. Whitman |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| Troutman Pepper Locke LLP<br> 400 Berwyn Park, 899 Cassatt Road<br> Berwyn, PA 19312-1183<br>troutman.com | ![](tm2517141d1_ex5-1img001.jpg) |

---

June 5, 2025

Amicus Therapeutics, Inc.

47 Hulfish Street

Princeton, New Jersey 08542

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

Reference is made to the registration statement on Form S-8 (the "***Registration Statement***") of Amicus Therapeutics, Inc., a Delaware corporation (the "***Company***"), filed on the date hereof with the Securities and Exchange Commission (the "***Commission***"), under the Securities Act of 1933, as amended (the "***Act***"). The Registration Statement covers an aggregate of (i) 17,476,463 shares (the "***2025 Plan Shares***") of the Company's common stock, par value $0.01 per share issuable pursuant to the Company's 2025 Equity Incentive Plan (the "***2025 Plan***") and (ii) 7,783,410 shares (the "***2007 Plan Shares***" and together with the 2025 Plan Shares, the "***Shares***") of the Company's common stock, par value $0.01 per share issuable pursuant to the Company's Amended and Restated 2007 Equity Incentive Plan (the "***2007 Plan***" and together with the 2025 Plan, each a "***Plan***" and collectively, the "***Plans***").

For purposes of this opinion letter, we have examined the Registration Statement, including the exhibits thereto, the originals or copies, certified or otherwise identified to our satisfaction, of the Company's Restated Certificate of Incorporation, as amended, the Company's Second Amended and Restated By-laws, the Plans and such other agreements, instruments and documents as we have deemed appropriate in rendering this opinion. As to matters of fact, we have relied on certain representations of officers of the Company.

In our examination of the aforesaid documents and rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents; the legal capacity of all natural persons; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as certified or photocopies; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness and authenticity of certificates issued by any governmental official, office or agency and the absence of change in the information contained therein from the effective date of any such certificate; and the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents.

This opinion letter is based as to matters of law solely on the General Corporation Law of the State of Delaware, as amended. We express no opinion herein as to any other statutes, rules or regulations. We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof.

Based on, subject to and limited by the foregoing, we are of the opinion that, following the (i) effectiveness of the Registration Statement, (ii) issuance of the Shares in accordance with the terms of the applicable Plan and (iii) receipt by the Company of the consideration for the Shares specified in the applicable resolutions of the Board of Directors or a duly authorized committee thereof, the Plans or any underlying award agreements or letters, the Shares will be validly issued, fully paid and non-assessable.

---

| | |
|:---|:---|
| Amicus Therapeutics, Inc.<br> Page 2 | ![](tm2517141d1_ex5-1img001.jpg) |

---

This opinion letter has been prepared for use in connection with the Registration Statement. This opinion letter is given as of the date hereof, and we express no opinion as to the effect of subsequent events or changes in law occurring or becoming effective after the date hereof. We assume no obligation to update this opinion letter or otherwise advise you with respect to any facts or circumstances or changes in law that may hereafter occur or come to our attention.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Troutman Pepper Locke LLP |
| Troutman Pepper Locke LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement (Form S-8) pertaining to the 2025 Equity Incentive Plan and the Amended and Restated 2007 Equity Incentive Plan of Amicus Therapeutics, Inc., of our reports dated February 19, 2025, with respect to the consolidated financial statements of Amicus Therapeutics, Inc., and the effectiveness of internal control over financial reporting of Amicus Therapeutics, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Iselin, New Jersey

June 5, 2025

## Exhibit 99.2

**EXHIBIT 99.2**

**AMICUS THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN**

**1.** **Purpose** 

The Amicus Therapeutics, Inc. 2025 Equity Incentive Plan (the ''Plan'') is intended to encourage share ownership by employees, consultants, directors and other service providers of Amicus Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the ''Company'') and its affiliates, and to provide an additional incentive for them to promote the success of the Company's business. Upon the Plan's Effective Date (as defined below), no further awards shall be made under the Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan (the ''Prior Plan'').

**2.** **Definitions** 

As used in the Plan the following terms shall have the respective meanings set out below:

&nbsp;&nbsp;&nbsp;&nbsp;**2.1** '' *Adoption Date* '' shall have the meaning ascribed to such term in Section 3.

&nbsp;&nbsp;&nbsp;&nbsp;**2.2** '' *Affiliate* '' means, with respect to any person or entity, any other person
or entity directly or indirectly controlling, controlled by or under common control with the first person or entity.

&nbsp;&nbsp;&nbsp;&nbsp;**2.3** '' *Award* '' means any grant under the Plan of Options, Stock Appreciation
Rights, Restricted Stock, Restricted Stock Units, Stock Grants, Other Stock Based Awards or Performance Awards.

&nbsp;&nbsp;&nbsp;&nbsp;**2.4** '' *Award Agreement* '' means an agreement between the Company and the recipient
of an Award, setting forth the terms and conditions of the Award.

&nbsp;&nbsp;&nbsp;&nbsp;**2.5** '' *Board* '' means the Company's board of directors.

&nbsp;&nbsp;&nbsp;&nbsp;**2.6** '' *Cause* '' shall have the meaning ascribed to such term in the
 Participant's employment or similar agreement; or if the Participant has no such agreement or if the term
 ''Cause'' is not defined in such agreement, then ''Cause'' has the following
 meaning: (i) willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on
 the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of the Participant to
 the detriment of the Company (or an Affiliate); (ii) violation of Company policy including, but not limited to, policies
 prohibiting harassment and other workplace misconduct, and policies governing corporate compliance; (iii) misappropriation of
 the funds or assets of the Company (or an Affiliate); (iv) conviction, plea of guilty, admission to facts sufficient for a
 finding of guilt, or plea of no contest (or nolo contendere) to: (a) any felony, or (b) any misdemeanor involving fraud,
 theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion; (v) material breach of the
 Participant's employment agreement, if any; (vi) material breach of the Participant's Confidentiality,
 Non-Disclosure and Non-Competition Agreement, if any, or any other restrictive covenant agreement; (vii) breach of the
 Participant's duty of loyalty to the Company (or an Affiliate); (viii) disqualification, bar or suspension by any
 governmental authority from performing any of the Participant's duties to the Company (or an Affiliate); (ix) material
 failure to perform the Participant's duties or obligations to the Company (or an Affiliate), other than as a result of being
 ''Unable to Work'' (which means the determination by the Company, following an interactive process, that the
 Participant has become physically or mentally incapable of performing the Participant's essential job functions, with or
 without a reasonable accommodation, following any period during which such status would be protected under applicable law);
 or (x) willful failure to adhere to or
carry out lawful duties or directives of the Participant's direct or indirect supervisor or the Board. Notwithstanding anything
to the contrary herein, the Company shall not be deemed to have terminated the Participant's employment or service for Cause for
the events described above in subsections (ix) or (x) unless the Company or Board, as applicable, has determined that such events
are amenable to cure and given the Participant written notice of the occurrence of the claimed event(s) constituting Cause and the
Participant has failed to cure such event(s) within fourteen (14) calendar days after the Participant's receipt of such notice
(or such other period as may be deemed reasonable by the Company or Board under the circumstances and communicated to the Participant).
The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation
into those events and provide the Participant a full opportunity to participate.

&nbsp;&nbsp;&nbsp;&nbsp;**2.7** '' *Change in Control* '' means any of the following: (i) when any person
or entity who is not a stockholder of the Company (as of the Effective Date of this Plan) becomes the beneficial owner of greater than
50% of the then-outstanding voting power of the Company; (ii) when a merger or consolidation with another entity occurs that causes
the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power
of the voting securities of the Company or the surviving entity outstanding immediately after the transaction; or (iii) when a sale
or disposition of all or substantially all of the Company's assets occurs. Notwithstanding anything in the Plan or an Award Agreement
to the contrary, no event shall be a Change in Control under the Plan or an Award Agreement unless such event is also a ''change
in control event'' as defined in Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;**2.8** '' *Code* '' means the Internal Revenue Code of 1986, as amended from time
to time, or any successor statute thereto, and any regulations issued from time to time thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;**2.9** '' *Committee* '' means any committee of the Board delegated responsibility
by the Board for the administration of the Plan, as provided in Section 5 of the Plan. Unless otherwise determined by the Board,
the Compensation and Leadership Development Committee of the Board will serve as the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;**2.10** '' *Common Stock* '' means shares of common stock, par value $0.01 per share,
of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;**2.11** '' *Company* '' shall have the meaning ascribed to such term in Section 1
above.

&nbsp;&nbsp;&nbsp;&nbsp;**2.12** '' *Corporate Transaction* '' means a reorganization, merger, statutory share
exchange, consolidation, sale of all or substantially all of the Company's assets, or the acquisition of assets or stock of another
entity by the Company, or other corporate transaction involving the Company or any of its Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;**2.13** '' *Disability* '' will be determined under any long-term disability plan
or policy maintained by the Company or an Affiliate and applicable to the Participant (or if no such plan or policy exists, ''Disability''
will mean a condition rendering the Participant disabled, within the meaning of Section 409A(a)(2)(C)(i) of the Code). Notwithstanding
anything in the Plan or an Award Agreement to the contrary, to the extent necessary to comply with Section 409A of the Code, no Disability
shall be deemed to have occurred unless it meets the requirements of Section 409A(a)(2)(C) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;**2.14** '' *Effective Date* '' shall have the meaning ascribed to such term in Section 3.

&nbsp;&nbsp;&nbsp;&nbsp;**2.15** '' *Exchange Act* '' means the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;**2.16** '' *Incentive Option* '' means an Option which by its terms is to be treated
as an ''incentive stock option'' within the meaning of Section 422 of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;**2.17** '' *Market Value* '' means the value of a share of Common Stock on a particular
date determined by such methods or procedures as may be established by the Committee. Unless otherwise determined by the Committee, the
Market Value of Common Stock as of any date is the closing price for the Common Stock as reported on the NASDAQ Global market (or on any
other national securities exchange on which the Common Stock is then listed) for that date or, if no closing price is reported for that
date, the closing price on the next preceding date for which a closing price was reported.

&nbsp;&nbsp;&nbsp;&nbsp;**2.18** '' *Non-Employee Director* '' has the meaning set forth in Rule 16b-3(b)(3)(i) promulgated
by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission.

&nbsp;&nbsp;&nbsp;&nbsp;**2.19** '' *Nonstatutory Option* '' means any Option that is not an Incentive Option.

&nbsp;&nbsp;&nbsp;&nbsp;**2.20** '' *Option* '' means an option granted under the Plan to purchase shares of
Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;**2.21** '' *Optionee* '' means an employee, consultant, director or other service
provider of the Company or an Affiliate to whom an Option shall have been initially granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**2.22** '' *Other Stock Based Award* '' means an Award other than an Option, Stock
Appreciation Right, Restricted Stock, Restricted Stock Unit, or Stock Grant, that is granted pursuant to Section 7.6 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**2.23** '' *Participant* '' means any holder of an outstanding Award under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**2.24** '' *Performance Award* '' means an Award that, pursuant to Section 7.7
is granted, vested and/or settled upon the achievement of specified Performance Goals.

&nbsp;&nbsp;&nbsp;&nbsp;**2.25** '' *Performance Goals* '' means individual or corporate goals established
by the Committee in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;**2.26** '' *Performance Period* '' means the period selected by the Committee during
which a Performance Goal is measured.

&nbsp;&nbsp;&nbsp;&nbsp;**2.27** '' *Plan* '' shall have the meaning ascribed to such term in Section 1
above.

&nbsp;&nbsp;&nbsp;&nbsp;**2.28** '' *Prior Plan* '' shall have the meaning ascribed to such term in Section 1
above.

&nbsp;&nbsp;&nbsp;&nbsp;**2.29** '' *Prior Plan Awards* '' means awards granted under the Prior Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**2.30** '' *Restricted Stock* '' means a grant under the Plan of shares of Common
Stock to a Participant subject to a Risk of Forfeiture.

&nbsp;&nbsp;&nbsp;&nbsp;**2.31** '' *Restricted Stock Units* '' means rights granted under the Plan to receive
shares of Common Stock subject to the fulfillment of Vesting Conditions.

&nbsp;&nbsp;&nbsp;&nbsp;**2.32** '' *Restriction Period* '' means the period of time, established by the Committee
in connection with an Award of Restricted Stock, during which the shares of Restricted Stock are subject to a Risk of Forfeiture described
in the applicable Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;**2.33** '' *Retirement* '' means a Participant's cessation of employment or
service with the Company or an Affiliate for any reason other than a termination by the Company or an Affiliate for Cause where (a) such
Participant has attained at least 5 years of continuous service with the Company and/or an Affiliate, (b) the Participant is at least
55 years of age, and (c) the sum of such Participant's age and years of service equals or exceeds 67 years.

&nbsp;&nbsp;&nbsp;&nbsp;**2.34** '' *Risk of Forfeiture* '' means a limitation on the right of a Participant
to retain an Award of Restricted Stock due to the failure to meet applicable Vesting Conditions.

&nbsp;&nbsp;&nbsp;&nbsp;**2.35** '' *Section 409A* '' means Section 409A of the Code, and the rules and
regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;**2.36** '' *Securities Act* '' means the US Securities Act of 1933, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;**2.37** '' *Separation* '' means the Participant's ''separation
from service'' from the Company and its Affiliates within the meaning of Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;**2.38** '' *Stock Appreciation Right* '' means a right granted under and subject to
Section 7.2 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**2.39** '' *Stock Grant* '' means a grant under Section 7.5 of the Plan of shares
of Common Stock not subject to restrictions or other forfeiture conditions.

&nbsp;&nbsp;&nbsp;&nbsp;**2.40** '' *Subsidiary* '' means, in respect of the Company, a subsidiary company
as defined in Sections 424(f) and (g) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;**2.41** '' *Ten Percent Owner* '' means a person who owns, or is deemed within the
meaning of Section 422(b)(6) (or 424(d)) of the Code to own, stock possessing more than 10% of the total combined voting power
of all classes of stock of the Company (or any parent or subsidiary corporations of the Company, as defined in Section 424(e) and
(f), respectively, of the Code). Whether a person is a Ten Percent Owner shall be determined with respect to each Option based on the
facts existing immediately prior to the grant date of such Option.

&nbsp;&nbsp;&nbsp;&nbsp;**2.42** '' *Vesting Conditions* '' means the continued employment or service of a
Participant, the attainment of Performance Goals, and/or such other factors as the Committee may determine in its sole discretion.

**3.** **Term of the Plan** 

The Plan was adopted by the Board on April 14, 2025, (the ''*Adoption Date*''), subject to approval by the Company's stockholders (the date of such approval, the ''Effective Date''). The Plan shall terminate automatically on the tenth anniversary of the Adoption Date, April 14, 2035, provided that it may be terminated on an earlier date as provided in Section 18. Awards granted pursuant to the Plan prior to its termination shall not expire solely by reason of the termination of the Plan.

**4.** **Stock Subject to the Plan** 

&nbsp;&nbsp;&nbsp;&nbsp;**4.1**  ***Shares Subject to the Plan.*** Subject to adjustment as
provided in Section 12.1 of the Plan, the maximum number of shares of Common Stock that may be issued in respect of Awards under
the Plan is equal to the sum of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) 9,000,000 shares of Common Stock, (ii) such additional number of shares of Common Stock as is equal to the number of shares of Common Stock reserved for issuance under the Prior Plan that remain available for grant under the Prior Plan on the Effective Date, and (iii) the number of shares of Common Stock underlying Prior Plan Awards that are outstanding as of the Effective Date (to the extent such shares of Common Stock become available for grant under the Plan pursuant to Section 4.4 hereof) (collectively, the ''Share Pool''). Any shares of Common Stock issued hereunder may consist, in whole or in part, of authorized and unissued shares or treasury shares.

&nbsp;&nbsp;&nbsp;&nbsp;**4.2**  ***Substitute Awards.*** Notwithstanding the foregoing, any
shares of Common Stock issued in respect of Awards granted in substitution for equity-based awards of an entity acquired by the Company
or a Subsidiary, or with which the Company or a Subsidiary combines, will not be counted against the number of shares of Common Stock
available for issuance hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;**4.3**  ***Incentive Option Limit.*** Subject to adjustment as provided
in Section 12.1 of the Plan, the maximum aggregate number of shares of Common Stock that may be issued under the Plan in respect
of Incentive Options is 9,000,000 shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;**4.4**  ***Effect of the Expiration or Termination of Awards.*** If
and to the extent that an Award or Prior Plan Award expires, terminates, is canceled or is forfeited for any reason, the shares of Common
Stock associated with that Award or Prior Plan Award (only to the extent of such expiration, termination, cancellation or forfeiture)
will again become available for grant under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;**4.5**  ***Share Recycling.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Other than with respect to an option or stock appreciation right granted under the Plan or the Prior Plan, shares of Common Stock
withheld in settlement of a tax withholding obligation associated with an Award or a Prior Plan Award shall be available for future issuance
under Section 4.1 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Notwithstanding anything in the Plan to the contrary, the following restrictions against liberal recycling of shares of Common Stock
shall apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The full number of shares of Common Stock subject to the exercise of an option (whether granted under the Plan or the Prior Plan)
shall be unavailable for future issuance under Section 4.1 of the Plan, even if the option exercise price is satisfied through net-settlement
or the delivery of shares of Common Stock to the Company (either by actual delivery or attestation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. The full number of shares of Common Stock subject to the exercise of a stock-settled stock appreciation right (whether granted under
the Plan or the Prior Plan) shall be unavailable for future issuance under Section 4.1 of the Plan, even though only a net number
of shares of Common Stock are delivered upon exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Shares of Common Stock withheld in settlement of a tax withholding obligation associated with an option or stock appreciation right
(whether granted under the Plan or the Prior Plan) shall be unavailable for future issuance under Section 4.1 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Shares of Common Stock repurchased on the open market with the proceeds from the exercise of an Award or Prior Plan Award shall be
unavailable for future issuance under Section 4.1 of the Plan.

**5.** **Administration** 

The Plan shall be administered by the Committee; provided, however, that at any time and on any one or more occasions the Board may itself exercise any of the powers and responsibilities assigned the Committee under the Plan and when so acting shall have the benefit of all of the provisions of the Plan pertaining to the Committee's exercise of its authorities hereunder; and provided further that subject to applicable law and the Company's governing documents, the Board or the Committee may delegate any of the authorities of the Committee identified herein to an individual or committee of individuals (who may, but need not, serve on the Board), including without limitation the authority to grant Awards hereunder to individuals who are not ''insiders'' within the meaning of Section 16 of the Exchange Act. To the extent that the Board or the Committee so delegates authority, applicable references in the Plan to the Committee's authority to make awards and determinations with respect thereto shall be deemed to include the delegate. Notwithstanding the foregoing, the Committee will retain broad authority to administer the Plan, including the authority to make determinations with respect to Awards previously granted by a delegate. The Board or the Committee, as applicable, may revoke any delegation it previously effectuated hereunder at any time, for any reason, with or without prior notice.

The authorities and responsibilities of the Committee under the Plan shall include, without limitation: (a) selecting each employee, consultant, director or other service provider to receive an Award; (b) selecting the applicable form of Award and terms and conditions of the Award; (c) determining whether an Option (if granted to an employee) will be an Incentive Option or a Nonstatutory Option; (d) determining the time of granting an Award; (e) determining the number of shares of Common Stock subject to an Award; (f) determining the exercise price, base price or purchase price for an Award and the method of payment; (g) determining the term of an Option or Stock Appreciation Right; (h) determining the Vesting Conditions (including the Performance Goals) of an Award; (i) notwithstanding anything in the Plan to the contrary, accelerating, waiving or shortening a Vesting Condition (including a Performance Goal) or accelerating the exercisability of an Award; (j) extending the period of time during which an Award may be exercised (but in no event beyond the expiration of the original Award term); (k) determining the effect of cessation of employment or service with the Company or any of its Affiliates on an Award; (l) determining whether Performance Goals to which an Award is subject are satisfied, including any adjustments thereto; and (m) modifying or amending an Award, subject to the Participant's consent if such modification or amendment would materially impair such Participant's rights under the Award. In making such determinations, the Committee may take into account the nature of the services rendered by the respective employees, consultants, directors and other service providers, their present and potential contributions to the success of the Company and its Affiliates, and such other factors as the Committee in its discretion shall deem relevant. Subject to the provisions of the Plan, the Committee shall also have complete authority to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, to determine the terms and provisions of the respective Award Agreements (which need not be identical), and to make all other determinations necessary or advisable for the administration of the Plan. The Committee's determinations made in good faith on matters referred to in the Plan shall be final, binding and conclusive on all persons having or claiming any interest under the Plan or an Award made pursuant hereto.

**6.** **Authorization and Eligibility** 

The Committee may grant Awards under the Plan to any employee, consultant, director or other service provider of the Company or its Affiliate. However, only employees of the Company or of any parent or subsidiary corporations of the Company, as defined in Sections 424(e) and (f), respectively, of the Code, shall be eligible for the grant of an Incentive Option.

Each grant of an Award shall be subject to all applicable terms and conditions of the Plan, and such other terms and conditions, not inconsistent with the terms of the Plan, as the Committee may prescribe.

**7.** **Specific Terms of Awards** 

&nbsp;&nbsp;&nbsp;&nbsp;**7.1**  ***Options.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  ***Type of Option.*** Options granted under the Plan may
either be Incentive Options or Nonstatutory Options. The Award Agreement evidencing each Option shall indicate the exercise price, the
term and the Vesting Conditions (if any) for such Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  ***Exercise Price.*** The price at which shares of Common
Stock may be acquired under each Option shall be not less than 100% of the Market Value of Common Stock on the grant date, or with respect
to a grant of an Incentive Option not less than 110% of the Market Value of Common Stock on the grant date if the Optionee is a Ten Percent
Owner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  ***Option Term.*** No Incentive Option or Nonstatutory Option
may be exercised after the tenth anniversary of the grant date, or after the fifth anniversary of the grant date in the case of an Incentive
Option in which the Optionee is a Ten Percent Owner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)  ***Exercisability.*** An Option may be immediately exercisable
or become exercisable based on the fulfillment of Vesting Conditions or at such other times as the Committee may determine. Any Option
may be a Performance Award, subject to Section 7.7. In the case of an Option not otherwise immediately exercisable in full, the Committee
may accelerate the exercisability of such Option in whole or in part at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)  ***Effect of Cessation of Employment or Service.*** Unless
the Committee shall provide otherwise with respect to any Option at or after grant, the following provisions shall apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. *Termination for Cause.* If the Optionee experiences a Separation due to a termination by the Company or its Affiliate for Cause,
(x) each Option (or portion thereof) not exercised, whether vested or unvested, will be immediately and automatically forfeited as
of the date of such Separation and (y) any shares of Common Stock that the Company has not yet delivered upon the prior exercise
of an Option, will be immediately and automatically forfeited and the Company will refund to the Participant the Option exercise price
paid for such shares, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. *Death.* If an Optionee dies during the Optionee's continued service, any unvested Options held by such Optionee that were
scheduled to vest in the future based solely upon the Optionee's continued service will become exercisable on the date of the Optionee's
death, and all of such Optionee's vested Options (including those that vest pursuant to the preceding clause) shall remain exercisable
until the earlier of (x) the 4th anniversary of the date
of the Optionee's death, and (y) the original expiration date of the term of the Option; any Options not exercised in such
period shall be forfeited with no further compensation due to the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. *Termination due to Disability or Retirement.* If the Optionee experiences a Separation due to the Optionee's Disability,
or Retirement, any unvested Options held by such Optionee that would have become vested and exercisable prior to the second anniversary
of such Optionee's Separation based solely on the Optionee's continued service through such time, will become exercisable
on the date of the Separation, and all of such Optionee's vested Options (including those that vest pursuant to the preceding clause)
shall remain exercisable until the earlier of (x) the 4th anniversary of the date of such Separation, and (y) the original expiration
date of the term of the Option; any Options not exercised in such period shall be forfeited with no further compensation due to the Participant.
In addition, any unvested Options that will not become exercisable at any time following the Separation pursuant to the preceding sentence
shall be immediately forfeited upon the Separation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. *Other Terminations.* If the Optionee experiences a Separation due to any reason other than a termination for Cause, death, Disability,
or Retirement, any unvested Options held by such Optionee shall be immediately forfeited and all vested Options held by such Participant
shall cease to be exercisable in any respect upon the earlier of (x) ninety (90) days following such Optionee's Separation,
and (y) the original expiration date of the term of the Option; any Options not exercised in such period shall be forfeited with no further compensation due to the Optionee. For Incentive Options, military or sick leave or other
 bona fide leave shall not be deemed a termination of employment, provided that it does not exceed the longer of ninety (90) days or
 the period during which the absent Optionee's reemployment rights, if any, are guaranteed by statute or by contract.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)  ***Method of Exercise.*** An Option may be exercised by a
Participant giving written notice to the Company (which may be electronically, including through the use of an alternative technological
platform made available by the Company) in the manner specified by the Company, specifying the number of shares of Common Stock to be
purchased. Such notice will be accompanied by payment in full of the exercise price either by certified or bank check, or such other means
as the Committee may accept. Unless otherwise determined by the Committee, payment of the exercise price of an Option may be made (i))
through means of a ''net settlement,'' whereby the Option exercise price will not be due in cash and where the
number of shares of Common Stock issued upon such exercise will be equal to: (A) the product of (i) the number of shares as
to which the Option is then being exercised, and (ii) the excess, if any, of (a) the then current market value over (b) the
Option exercise price, divided by (B) the then current market value, or (ii) under the terms and conditions of any formal cashless
exercise program authorized by the Company entailing the sale of the Common Stock subject to any Option in a brokered transaction (other
than to the Company). Notwithstanding any of the foregoing provisions in this subsection (f) to the contrary, no Option shall be
considered to have been exercised unless and until all of the provisions governing such exercise specified in the Plan and in the relevant
Award Agreement shall have been duly complied with.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)  ***Limit on Incentive Option Characterization.*** An
 Incentive Option shall be considered to be an Incentive Option only to the extent that the number of shares of Common Stock for
 which the Option first becomes exercisable in a calendar year does not have an aggregate Market Value (as of the date of the grant
 of the Option) in excess of the ''current limit.'' The current limit for any Optionee for any calendar year
 shall be $100,000 minus the aggregate Market Value at
the date of grant of the number of shares of Common Stock available for purchase for the first time in the same year under each other
Incentive Option previously granted to the Optionee under the Plan, and under each other incentive stock option previously granted to
the Optionee. Any shares of Common Stock which would cause the foregoing limit to be violated shall be deemed to have been granted under
a separate Nonstatutory Option, otherwise identical in its terms to those of the Incentive Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)  ***Notification of Disposition.*** Each person exercising
any Incentive Option granted under the Plan shall be deemed to have covenanted with the Company to report to the Company any disposition
of such shares prior to the expiration of the holding periods specified by Section 422(a)(1) of the Code and, if and to the
extent that the realization of income in such a disposition imposes upon the Company federal, state, local or other withholding tax requirements,
or any such withholding is required to secure for the Company an otherwise available tax deduction, to remit to the Company an amount
in cash sufficient to satisfy those requirements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  ***Rights Pending Exercise.*** No person holding an Option
shall be deemed for any purpose to be a stockholder of the Company with respect to any shares of Common Stock issuable pursuant to such
Option except to the extent that such Option shall have been exercised with respect thereto and shares shall have been issued therefor.

&nbsp;&nbsp;&nbsp;&nbsp;**7.2**  ***Stock Appreciation Right.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  ***General.*** Subject to the other terms of the Plan, the
Committee may grant Stock Appreciation Rights under the Plan. Each Stock Appreciation Right shall represent the right to receive, upon
exercise, an amount equal to the number of shares of Common Stock subject to the Award that is being exercised multiplied by the excess
of (i) the Market Value on the date the Award is exercised, over (ii) the base price specified in the applicable Award Agreement.
Distributions may be made in cash, shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing
each Stock Appreciation Right shall indicate the base price, the term and the Vesting Conditions for such Award. Any Stock Appreciation
Right may be a Performance Award, subject to Section 7.7. A Stock Appreciation Right base price may never be less than the Market
Value of the underlying common stock of the Company on the date of grant of such Stock Appreciation Right. The term of each Stock Appreciation
Right will be fixed by the Committee, but no Stock Appreciation Right will be exercisable more than 10 years after the date the Stock
Appreciation Right is granted. Subject to the terms and conditions of the applicable Award Agreement, Stock Appreciation Rights may be
exercised in whole or in part from time to time during their term by the delivery of written notice to the Company (which may be electronically,
including through the use of an alternative technological platform made available by the Company) in the manner specified by the Company,
specifying the portion of the Award to be exercised. No person holding a Stock Appreciation Right shall be deemed for any purpose to be
a stockholder of the Company with respect to any shares of Common Stock issuable pursuant to such Stock Appreciation Right except to the
extent that such Stock Appreciation Right shall have been exercised with respect thereto and shares shall have been issued therefor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  ***Effect of Cessation of Employment or Service.*** Unless
the Committee shall provide otherwise with respect to any Stock Appreciation Right at or after grant, the following provisions shall apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. *Termination for Cause.* If the Participant experiences a Separation due to a termination by the Company or its Affiliate for
Cause, (x) each Stock Appreciation Right (or portion thereof) not exercised, whether vested or unvested, will be immediately and
automatically forfeited as of the date of such Separation and (y) any shares of Common Stock that the Company has not yet delivered
upon the prior exercise of a Stock Appreciation Right, will be immediately and automatically forfeited, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. *Death.* If a Participant dies during the Participant's continued service, any unvested Stock Appreciation Rights held
by such Participant that were scheduled to vest in the future based solely upon the Participant's continued service will become
exercisable on the date of the Participant's death, and all of such Participant's vested Stock Appreciation Rights (including
those that vest pursuant to the preceding clause) shall remain exercisable until the earlier of (x) the 4th anniversary of the date
of the Participant's death, and (y) the original expiration date of the term of the Stock Appreciation Right; any Stock Appreciation
Rights not exercised in such period shall be forfeited with no further compensation due to the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. *Termination due to Disability or Retirement.* If the Participant experiences a Separation due to the Participant's Disability
or Retirement, any unvested Stock Appreciation Rights held by such Participant that would have become vested and exercisable prior to
the second anniversary of such Participant's Separation based solely on the Participant's continued service through such time,
will become exercisable on the date of the Separation, and all of such Participant's vested Stock Appreciation Rights (including
those that vest pursuant to the preceding clause) shall remain exercisable until the earlier of (x) the 4th anniversary of the date of such Separation,
and (y) the original expiration date of the term of the Stock Appreciation Right; any Stock Appreciation Rights not exercised in
such period shall be forfeited with no further compensation due to the Participant. In addition, any unvested Stock Appreciation Rights
that will not become exercisable at any time following the Separation pursuant to the preceding sentence shall be immediately forfeited
upon the Separation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. *Other Terminations.* If the Participant experiences a Separation due to any reason other than a termination for Cause, death,
Disability, or Retirement, any unvested Stock Appreciation Rights held by such Participant shall be immediately forfeited and all vested
Stock Appreciation Rights held by such Participant shall cease to be exercisable in any respect upon the earlier of (x) ninety (90)
days following such Participant's Separation, and (y) the original expiration date of the term of the Stock Appreciation Right;
any Stock Appreciation Rights not exercised in such period shall be forfeited with no further compensation due to the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;**7.3**  ***Restricted Stock.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  ***Purchase Price.*** The purchase price for Awards of Restricted
Stock under the Plan may, but need not, be zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  ***Issuance of Certificates.*** Upon the Award of Restricted
Stock, the Committee may direct that a certificate or certificates representing the number of shares subject to such Award be issued to
the Participant or placed in a restricted stock account (including an electronic account) with the transfer agent and in either case designating
the Participant as the registered owner. The certificate(s), if any, representing such shares shall be physically or electronically legended,
as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  ***Escrow of Shares.*** The Committee may require that any
stock certificates evidencing shares of Restricted Stock be held in custody by a designated escrow agent (which may but need not be the
Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock power, endorsed in blank, relating
to the Common Stock covered by such Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)  ***Restrictions and Restriction Period.*** During the Restriction
Period applicable to shares of Restricted Stock, such shares shall be subject to limitations on transferability and a Risk of Forfeiture
as specified in the Award Agreement. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at
any time by the Committee on such basis as it deems appropriate. Any Award of Restricted Stock may be a Performance Award, subject to
Section 7.7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)  ***Rights Pending Lapse of Risk of Forfeiture or Forfeiture of Award.*** Except
as otherwise provided in the Plan (including under Section 10 hereto) or the applicable Award Agreement, at all times prior to lapse
of any Risk of Forfeiture applicable to, or forfeiture of, an Award of Restricted Stock, the Participant shall have all of the rights
of a stockholder of the Company, including the right to vote the shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)  ***Effect of Cessation of Employment or Service.*** Unless
the Committee shall provide otherwise with respect to any Award of Restricted Stock at or after grant, the following provisions shall
apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. *Death.* If a Participant dies during the Participant's continued service, any unvested shares of Restricted Stock subject
to a Restriction Period that were scheduled to vest in the future based solely upon the Participant's continued service shall vest
on the date of the Participant's death.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. *Termination due to Disability or Retirement.* If the Participant experiences a Separation during the Restriction Period due
to the Participant's Disability or Retirement, then any unvested shares of Restricted Stock held by such Participant that were initially
scheduled to vest within the two-year period following the Participant's Separation based solely upon the Participant's continued
service during such time shall vest, and the restrictions thereon shall lapse and such shares of Restricted Stock shall become immediately
nonforfeitable (and all other shares of Restricted Stock that are subject to a Risk of Forfeiture will be forfeited upon such Separation
with no further compensation due to the Participant).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. *Other Terminations.* If the Participant experiences a Separation during the Restriction Period for any reason other than death,
Disability or Retirement (including without limitation a termination with or without Cause), then all outstanding unvested shares of Restricted
Stock granted to such Participant shall be forfeited or otherwise subject to return to or repurchase by the Company if and to the extent
so provided by, and subject to and in accordance with, the terms of the applicable Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;**7.4**  ***Restricted Stock Units.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  ***Character.*** Each Restricted Stock Unit shall entitle
the recipient to receive an amount equal to the Market Value of a share of Common Stock at the time of the distribution, following the
fulfillment of applicable Vesting Conditions (if any), at the time set forth in the Award Agreement. Payment in respect of a Restricted
Stock Unit Award may be made in cash, shares or both, in the discretion of the Committee. Any grant of Restricted Stock Units may be a
Performance Award, subject to Section 7.7.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  ***Effect of Cessation of Employment or Service.*** Unless
the Committee shall provide otherwise with respect to any Award of Restricted Stock Units at or after grant, the following provisions
shall apply to Restricted Stock Units that vest solely based on the continued employment or service of a Participant (''Time-Based
RSUs'') and Restricted Stock Units that vest both based on the continued employment or service of the Participant and one
or more Performance Goals (''Performance-Based RSUs''):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. *Termination for Cause.* If the Participant experiences a Separation due to a termination by the Company or its Affiliate for
Cause, each Time-Based RSU and Performance-Based RSU, whether vested or unvested, will be immediately and automatically forfeited as of
the date of such Separation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. *Death.* If the Participant dies during the Participant's continued service, then:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.* all outstanding unvested Time-Based RSUs that were initially scheduled to vest in the future based solely upon the Participant's
continued service shall vest, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*2.* to the extent the Participant's death occurs during an open Performance Period under outstanding Performance-Based RSUs, such
Performance-Based RSUs will vest at the target (100%) level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. *Termination due to Disability or Retirement.* If the Participant experiences a Separation due to Disability or Retirement, then:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.* any outstanding unvested Time-Based RSUs that were initially scheduled to vest within the two year period following the Participant's
Separation based solely upon the Participant's continued service shall vest (and all other unvested Time-Based RSUs that were initially
scheduled to vest following the two year period following the Participant's Separation based solely upon the Participant's
continued service during such time will be forfeited upon such Separation with no further compensation due to the Participant), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*2.* to the extent the Separation occurs during an open Performance Period under outstanding Performance-Based RSUs, a pro-rata portion
(based on the number of completed days prior to the Participant's Separation during the applicable Performance Period divided by
the total number of days in the applicable Performance Period) will remain eligible to vest after the Participant's Separation,
to the extent earned based on the actual achievement of the Performance Goals through the end of the applicable Performance Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. *Other Terminations*. If the Participant experiences a Separation for any reason other than death, Disability, or Retirement,
then all unvested Time-Based RSUs and Performance-Based RSUs shall be forfeited.

To the extent vested, Time-Based RSUs and Performance-Based RSUs will be settled on the date specified in the applicable Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  ***Rights Pending Fulfillment of Vesting Conditions and Issuance of Shares.*** No
person holding Restricted Stock Units shall be deemed for any purpose to be a stockholder of the Company with respect to any of the shares
of Common Stock subject to such Restricted Stock Units, except to the extent that the Vesting Conditions have been fulfilled and shares
have actually been issued thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;**7.5**  ***Stock Grants.*** Stock Grants may be awarded in such circumstances
as the Committee deems appropriate, including without limitation in recognition of significant contributions to the success of the Company
or its Affiliates or in lieu of compensation otherwise already due, subject to applicable law. Stock Grants shall be made without forfeiture
conditions of any kind. The purchase price for Stock Grants under the Plan may, but need not, be zero.

&nbsp;&nbsp;&nbsp;&nbsp;**7.6**  ***Other Stock Based Awards.*** Subject to the other terms
of the Plan, the Committee may grant Other Stock Based Awards to eligible individuals. The Award Agreement evidencing an Other Stock Based
Award shall set forth the terms and conditions of such Other Stock Based Award, including, as applicable, the term, any exercise or purchase
price, Vesting Conditions and other terms and conditions. Any grant of an Other Stock Based Award may be a Performance Award, subject
to Section 7.7. Payment by the Company to the Participant in respect of an Other Stock Based Award may be made in cash, shares, or
a combination of cash and shares, as determined by the Committee.

&nbsp;&nbsp;&nbsp;&nbsp;**7.7**  ***Performance Awards.*** The Committee may grant Performance
Awards in accordance with this Section. Performance Awards may be denominated as a number of shares of Common Stock which may be earned
upon achievement or satisfaction of Performance Goals, as specified by the Committee. In addition, the Committee may specify that any
other Award shall constitute a Performance Award by conditioning the vesting or settlement of the Award upon the achievement or satisfaction
of such Performance Goals.

&nbsp;&nbsp;&nbsp;&nbsp;**7.8**  ***Awards to Participants Outside the United States.*** To
facilitate compliance with the laws in countries other than the United States in which the Company and/or any of its respective Affiliates
operate or have employees, consultants, directors or other service providers, or the requirements of any foreign securities exchange or
other applicable law, or to otherwise ensure the viability of the benefits from Awards granted to employees, consultants, directors, or
other service providers performing services in such countries and to meet the objectives of the Plan, the Committee, in its discretion,
shall have the power and authority to: (i) modify the terms and conditions of any Award granted to employees, consultants, directors,
or other service providers based outside the United States; (ii) establish sub-plans and modify
procedures, to the extent such actions may be necessary or advisable, including adoption of rules, procedures or sub-plans applicable
to particular Affiliates or Participants in particular locations; provided, however, that no such sub-plans and/or modifications shall
increase the share limitations contained in Section 4.1 and (iii) take any action, before or after an Award is made, that it
deems advisable to obtain approval or facilitate compliance with any necessary local governmental regulatory exemptions, approvals or
requirements. Without limiting the generality of the foregoing, the Committee is specifically authorized to adopt rules, procedures and
sub-plans with provisions that limit or modify eligibility to receive an Award under the Plan or the effects of death, disability, retirement
or other termination of employment, available methods of exercise or settlement of an Award, payment of income, social insurance contributions
and payroll taxes, the shifting of employer tax or social insurance contribution liability to the Participant, withholding procedures
and handling of any share certificates or other indicia of ownership. Notwithstanding the foregoing, the Committee may not take any actions
hereunder, and no Awards shall be granted, that would violate applicable law. For the avoidance of doubt, to the extent that any Committee
action described under the foregoing paragraph requires stockholder approval under applicable law, then such action shall be subject to
stockholder approval.

**8.** **Minimum Vesting** 

Awards shall be subject to a minimum vesting period of one year from the date of grant, provided that Awards covering up to 5% of the Share Pool shall not be subject to such minimum vesting period. Notwithstanding the foregoing, an Award Agreement may provide that Awards vest sooner in connection with a Change in Control or the Participant's cessation of employment or service. For the avoidance of doubt, nothing herein limits or constrains the Committee's ability to accelerate the vesting of an Award for any reason pursuant to Section 5 of the Plan.

**9.** **Transferability** 

No Award or other right or interest of a Participant under the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company or an Affiliate, or assigned or transferred by such Participant other than by will or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or the Participant's guardian or legal representative. Notwithstanding the foregoing, unless otherwise determined by the Committee, Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Option) shall be transferable pursuant to a bona fide divorce agreement or settlement delineating the division of assets between a divorcing Participant and Participant's spouse, to the extent permissible under applicable law. In addition, the Committee may, in its discretion, provide that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Option) be transferable, without consideration, to a ''family member'' within the meaning of Form S-8 under the Securities Act. The Committee may attach to such transferability feature such terms and conditions as it deems advisable. In addition, if permitted by the Committee in its discretion, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a person or a trust) to exercise the surviving rights of the Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. If the Committee does not so permit, or the Participant has not designated a beneficiary (or if any permitted beneficiary designation is later determined to be invalid), then following the Participant's death, the estate will succeed to any such surviving rights. A beneficiary, a guardian, a legal representative, an estate or any other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee.

**10.** **Dividends and Dividend Equivalent Rights** 

&nbsp;&nbsp;&nbsp;&nbsp;**10.1** Notwithstanding anything in the Plan to the contrary:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No dividends or dividend equivalent rights will be payable with respect to Options or Stock Appreciation Rights; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any dividends, or dividend equivalent rights payable on any other type of Award will be subject to the same Vesting Conditions as
the underlying Award (or portion thereof) to which such amounts relate. Specifically:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Dividends that become payable with respect to a share of Restricted Stock while it remains subject to restriction will be subjected
to the same Restriction Period as is applicable to the Restricted Stock with respect to which such amounts are paid, or, if the Committee
so determines, reinvested in additional Restricted Stock to the extent shares of Common Stock are available under Section 4.1 of
the Plan, which additional Restricted Stock shall also be subjected to the same Restriction Period; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. An Award Agreement for Restricted Stock Units or Other Stock Based Award may provide for the inclusion of dividend equivalent rights
entitling a Participant to payments or credits equal to the cash dividends that would otherwise have been paid with respect to the share
of Common Stock subject to an Award, had such shares been outstanding. The Committee may provide that such dividend equivalent rights
will be paid or credited in cash or paid or credited in shares of Common Stock (based on the Market Value on the dividend payment date).
Any such dividend equivalent payments or credits shall be subject to the same Vesting Conditions as the underlying Award (or portion thereof)
to which they relate.

**11.** **Annual Compensation Limits for Non-Employee Directors** 

Beginning with the first fiscal year following the fiscal year in which the Effective Date occurs, the aggregate amount of equity and cash compensation payable to a Non-Employee Director with respect to a fiscal year, whether under the Plan or otherwise, for services as a Non-Employee Director, shall not exceed $750,000; provided however, that such amount shall be $1,000,000 for the fiscal year in which the applicable Non-Employee Director is initially elected or appointed to the Board (collectively, the ''Director Limit''). Equity incentive awards shall be counted towards the Director Limit in the fiscal year in which they are granted, based on the grant date fair value of such awards for financial reporting purposes (but excluding the impact of estimated forfeitures related to service-based vesting provisions). Cash fees shall be counted towards the Director Limit in the fiscal year for which they are reported as compensation in the Company's director compensation disclosures pursuant to Item 402 of Regulation S-K under the Securities Act, or a successor provision. The Director Limit shall not apply to (i) equity and cash compensation earned by a Non-Employee Director solely in the Participant's capacity as chairperson of the Board or lead independent director; (ii) equity and cash compensation earned with respect to services a Non-Employee Director provides in a capacity other than as a Non-Employee Director, such as an advisor or consultant to the Company; and (iii) equity and cash compensation awarded by the Board to a Non-Employee Director in extraordinary circumstances, as determined by the Board in its discretion, in each case provided that the Non-Employee Director receiving such additional compensation does not participate in the decision to award such compensation.

**12.** **Adjustments and Corporate Events** 

&nbsp;&nbsp;&nbsp;&nbsp;**12.1**  ***Adjustment for Corporate Actions.*** If, subsequent to
the Effective Date, the outstanding shares of Common Stock (or any other securities covered by the Plan by reason of the prior application
of this Section) are increased, decreased, or exchanged for a different number or kind of shares or other securities, or if additional
shares or new or different shares or other securities are distributed with respect to such shares of Common Stock or other securities,
through merger, consolidation, sale of all or substantially all the property of the Company, reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, or other distribution with respect to such shares of Common Stock, or other securities, the
Committee shall make equitable adjustments in such manner as it deems appropriate to (i) the maximum numbers and kinds of
shares provided in Section 4, (ii) the numbers and kinds of shares or other securities subject to the then outstanding
Awards, (iii) the exercise price for each share or other unit of any other securities subject to then outstanding Options and
Stock Appreciation Rights (without change in the aggregate purchase price as to which such Options and Stock Appreciation Rights
remain exercisable), (iv) the Performance Goal(s) applicable to any outstanding Performance Award, and/or (v) any
other affected terms and conditions of the Plan or outstanding Awards.

&nbsp;&nbsp;&nbsp;&nbsp;**12.2**  ***Corporate Transaction.*** Unless otherwise specified in
the applicable Award Agreement, and subject to the provisions of Section 12.3, in the event of a Corporate Transaction, the Plan
and the Awards issued hereunder shall continue in effect in accordance with their respective terms, except that following a Corporate
Transaction either (i) each outstanding Award shall be
treated as provided for in the agreement entered into in connection with the Corporate Transaction, or (ii) if not so provided in
such agreement, each Participant shall be entitled to receive in respect of each share of Common Stock subject to an outstanding Award,
upon exercise or payment or transfer in respect of an Award, the same number and kind of stock, securities, cash, property or other consideration
that each holder of a share of Common Stock was entitled to receive in the Corporate Transaction in respect of a share; provided, however,
that, unless otherwise determined by the Committee, such stock, securities, cash, property or other consideration shall remain subject
to all of the conditions, restrictions and performance criteria which were applicable to the Award prior to such Corporate Transaction.
Without limiting the generality of the foregoing, the treatment of outstanding Options and Stock Appreciation Rights pursuant to this
Section 12.2 in connection with a Corporate Transaction may include the cancellation of outstanding Options and Stock Appreciation
Rights upon consummation of the Corporate Transaction as long as, at the election of the Committee, (i) the holders of affected Options
and Stock Appreciation Rights have been given an opportunity to exercise the Options or Stock Appreciation Rights (to the extent otherwise
exercisable) immediately prior to (and contingent upon the occurrence of) the Corporate Transaction or (ii) the holders of the affected
Options and Stock Appreciation Rights are paid (in cash or cash equivalents) in respect of each share of Common Stock covered by the Option
or Stock Appreciation Right being canceled an amount equal to the excess, if any, of the per share price paid or distributed to stockholders
in the Corporate Transaction (the value of any non-cash consideration to be determined by the Committee in its sole discretion) over the
exercise price or base price, as applicable. For avoidance of doubt, (1) the cancellation of Options and Stock Appreciation Rights
pursuant to clause (ii) of the preceding sentence may be effected notwithstanding anything to the contrary contained in this Plan
or any Award Agreement and (2) if the amount determined pursuant to clause (ii) of the preceding sentence is zero or less, the
affected Option or Stock Appreciation Right may be cancelled without any payment therefore. The Committee need not treat each Award in
a uniform manner under this Section 12.2.

&nbsp;&nbsp;&nbsp;&nbsp;**12.3**  ***Consequences of a Change in Control.*** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Unless otherwise specified in the applicable Award Agreement, all time-based Vesting Conditions of outstanding Awards held by a Non-Employee
Director shall be deemed fulfilled upon a Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless otherwise specified in the applicable Award Agreement, all outstanding Awards held by a Participant that is not a Non-Employee
Director shall be treated as follows upon a Change in Control:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The Committee may in its discretion, without the need for the consent of any Participant, arrange for the assumption, conversion or
replacement of any such outstanding Awards upon a Change in Control. To the extent such Awards are assumed, converted or replaced by the
resulting entity in the Change in Control, if, within one year after the date of the Change in Control, the Participant's service
is terminated by the Company (or the resulting entity in the Change in Control) without Cause, then (x) all time-based Vesting Conditions
shall be deemed fulfilled, and (y) performance-based Vesting Conditions shall be deemed fulfilled at the greater of the ''target''
performance level or the ''actual'' level of achievement through the Participant's termination date (or
other reasonably proximate date selected by the Committee based on the availability of relevant data), as determined by the Committee
in its discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. To the extent such Awards are not assumed, converted or replaced by the resulting entity in the Change in Control, then upon the Change
in Control, (x) all time-based Vesting Conditions shall be deemed fulfilled, and (y) performance-based Vesting Conditions shall
be deemed fulfilled at the greater of the ''target'' performance level or the ''actual''
level of achievement through the Change in Control (or other reasonably proximate date selected by the Committee based on the availability
of relevant data), as determined by the Committee in its discretion.

Notwithstanding any provision of this Section 12.3, in the case of any Award subject to Section 409A, the Committee shall only be permitted to take actions under this Section 12.3 to the extent that such actions would be consistent with the intended treatment of such Award under Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;**12.4**  ***Dissolution or Liquidation.*** Upon dissolution or liquidation
of the Company, each outstanding Option shall terminate, but the Optionee (if at the time the Optionee has an employment, consulting or
Board member relationship with the Company or any of its Affiliates) shall have the right, immediately prior to such dissolution or liquidation,
to exercise the Option to the extent exercisable on the date of such dissolution or liquidation.

&nbsp;&nbsp;&nbsp;&nbsp;**12.5**  ***Related Matters.*** Any adjustment in Awards made pursuant
to this Section 12 shall be determined and made, if at all, by the Committee and shall include any correlative modification of terms,
including of Option exercise prices and Stock Appreciation Right base prices, rates of vesting or exercisability, Risks of Forfeiture,
adjustment of Performance Goals and/or Performance Periods and applicable repurchase prices for Restricted Stock, which the Committee
may deem necessary or appropriate so as to ensure that the rights of the Participants in their respective Awards are not substantially
diminished nor enlarged as a result of the adjustment and corporate action other than as expressly contemplated in this Section 12.
No fraction of a share shall be purchasable or deliverable upon exercise, but in the event any adjustment hereunder of the number of shares
covered by an Award shall cause such number to include a fraction of a share, such number of shares shall be adjusted to the nearest smaller
whole number of shares. No adjustment of an Option exercise price or Stock Appreciation Right base price per share pursuant to this Section 12
shall result in an exercise price which is less than the par value of the Common Stock.

**13.** **Conditions Upon Grant of Awards and Issuance of Shares** 

&nbsp;&nbsp;&nbsp;&nbsp;**13.1** The implementation of the Plan, the grant of any Award and the issuance of shares of Common Stock in
connection with the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company's procurement
of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and
the shares issuable pursuant to those Awards.

&nbsp;&nbsp;&nbsp;&nbsp;**13.2** No shares of Common Stock or other assets shall be issued or delivered under the Plan unless and until
there shall have been compliance with all applicable requirements of applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;**13.3** If the Company cannot, by the exercise of commercially reasonable efforts, obtain authority from any
regulatory body having jurisdiction over the issuance or sale of shares of Common Stock under the Plan, and such authority is deemed by
the Company's counsel to be necessary to the lawful issuance of those shares, the Company will be relieved of any liability for
failing to issue or sell those shares.

&nbsp;&nbsp;&nbsp;&nbsp;**13.4** The Committee may require each Participant to represent to and agree with the Company in writing that
the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as to such
other matters as the Committee believes are appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;**13.5** All shares of Common Stock or other securities delivered under the Plan will be subject to such stop-transfer
orders and other restrictions as the Committee may deem necessary to reflect the terms of the applicable Award or advisable to comply
with the rules, regulations and other requirements of the Securities Act, the Exchange Act, any stock exchange upon which the Shares are
then listed, and any other applicable law, and the Committee may cause shares of Common Stock or other securities to be legended to reflect
those restrictions.

**14.** **Tax Withholding** 

Whenever a taxable or tax withholding event occurs with respect to any Award under the Plan, the Participant will pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any federal, foreign, state or local taxes of any kind required by law to be withheld with respect to such amount, in such method or methods approved by the Compensation and Leadership Development Committee of the Board. Unless otherwise determined by the Compensation and Leadership Development Committee of the Board, the tax withholding method that must be used for all Awards under the Plan shall be ''share withholding,'' which means the withholding of shares of Common Stock subject to the Award based on the market value of those shares (but not in excess of the amount determined based on the maximum statutory tax rate in the applicable jurisdiction) . Notwithstanding the foregoing, the Compensation and Leadership Development Committee of the Board is not restricted from modifying the method(s) approved for tax withholding at a future date. Such methods could include, without limitation, the implementation of a formal cashless exercise program authorized by the Company entailing the sale of the Common Stock subject to an Award in a brokered transaction (other than to the Company) to fulfill withholding obligations, subject to the approval of the Compensation and Leadership Development Committee of the Board. The obligations of the Company under the Plan will be conditioned on such payment or arrangements and the Company or an Affiliate will have the right to deduct any such taxes from any payment of any kind otherwise due to the Participant.

**15.** **No Special Service Rights** 

Nothing contained in the Plan or in any Award Agreement shall confer upon any recipient of an Award any right with respect to the continuation of the recipient's employment, consulting or Board member relationship or other association with the Company (or any Affiliate), or interfere in any way with the right of the Company (or any Affiliate), subject to the terms of any separate employment, consulting or Board member agreement or provision of law or corporate articles or by-laws to the contrary, at any time to terminate such employment, consulting or Board member agreement or to increase or decrease, or otherwise adjust, the other terms and conditions of the recipient's employment, consulting or Board member relationship or other association with the Company and its Affiliates.

**16.** **Nonexclusivity of the Plan** 

Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders of the Company shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of stock options, stock appreciation rights, restricted stock and restricted stock units other than under the Plan, and such arrangements may be either applicable generally or only in specific cases.

**17.** **No Restriction on Corporate Action** 

The grant of any Award will not in any way affect the right or power of the Company to make adjustments, reclassification or changes in its capital or business structure or to merge, consolidate, dissolve, liquidate, sell or transfer all or any part of its business or assets.

**18.** **Termination and Amendment of the Plan** 

Subject to any stockholder approval that may be required under applicable law, the Board may amend or terminate the Plan at any time.

**19.** **Repricing Prohibited** 

Neither the Committee nor the Board may (i) implement any cancellation/re-grant program pursuant to which outstanding Options or Stock Appreciation Rights under the Plan are cancelled and new Options or Stock Appreciation Rights are granted in replacement with a lower exercise or base price per share, (ii) cancel outstanding Options or Stock Appreciation Rights under the Plan with exercise prices or base prices per share in excess of the then current Market Value for consideration payable in equity securities of the Company or cash or (iii) otherwise directly reduce the exercise price or base price in effect for outstanding Options or Stock Appreciation Rights under the Plan, without in each such instance obtaining stockholder approval.

**20.** **Company Policies** 

The Awards (whether vested or unvested) shall be subject to the Company's stock ownership policies, hedging and pledging policies, and any current or future clawback, recoupment or similar policy of the Company covering the Participant, including without limitation the Amicus Therapeutics, Inc. Clawback Policy. Notwithstanding any other provisions in the Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawbacks as may be made thereunder.

**21.** **Section 409A** 

Awards granted under the Plan are intended to comply with or be exempt from Section 409A, and the Plan shall be interpreted and administered accordingly. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participant's ''separation from service'' within the meaning of Section 409A, shall instead be paid on the next business day after the six month anniversary of the Participant's ''separation from service'' (or the Participant's death, if earlier). Each amount to be paid or benefit to be provided under the Plan shall be construed as a separate and distinct payment for purposes of Section 409A. A Participant shall not be considered to have terminated employment or service with the Company or an Affiliate for purposes of any payments under the Plan which are subject to Section 409A until the Participant would be considered to have incurred a ''separation from service.'' Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on a Participant under Section 409A and neither the Company nor the Committee will have any liability to Participants or any other persons for such tax or penalty.

**22.** **Notices and Other Communications** 

Any notice to be given to the Company pursuant to the provisions of the Plan must be given in writing and addressed, if to the Company, to its principal executive office to the attention of its Chief Legal Officer (or such other person as the Company may designate in writing from time to time), and, if to the Participant, to the address contained in the Company's personnel files, or at such other address as that Participant may hereafter designate in writing to the Company. Any such notice will be deemed duly given: if delivered personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5) days after the date of mailing by registered or certified mail.

**23.** **Governing Law** 

The Plan and all Award Agreements and actions taken thereunder shall be governed, interpreted and enforced in accordance with the laws of Delaware, without regard to the conflict of laws principles thereof.

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **AMICUS THERAPEUTICS, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.01 par value per share, reserved for issuance pursuant to the Registrant's 2025 Equity Incentive Plan | Other | 17476463 | $6.12 | $106955953.56 | 0.0001531 | $16374.96 |
| 2 | Equity | Common Stock, $0.01 par value per share, reserved for issuance pursuant to the Registrant's Amended and Restated 2007 Equity Incentive Plan | Other | 7783410 | $6.12 | $47634469.20 | 0.0001531 | $7292.84 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $154590422.76  |  | $23667.80  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $23667.80  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Consists of shares of common stock, par value $0.01 per share ("Common Stock") of Amicus Therapeutics, Inc. (the "Registrant") reserved for issuance under the Registrant's 2025 Equity Incentive Plan (the "2025 Plan"). Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the 2025 Plan by reason of any future stock dividend, stock split, reverse stock split, recapitalization, merger, consolidation, reorganization, reclassification, combination, exchange of shares or similar event or change in the Registrant's capital stock. Estimated in accordance with Rule 457(h)(1) under the Securities Act solely for purposes of calculating the registration fee, based on the average of the high and low sales prices for the Common Stock as reported on the NASDAQ Global Market on May 30, 2025, or $6.12 (rounded up to the nearest cent).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Represents shares of Common Stock issuable pursuant to options, restricted stock units and performance restricted stock units under the Registrant's Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan") immediately prior to the filing of this Registration Statement. The 2007 Plan has been terminated, and no further equity awards will be made pursuant to the 2007 Plan.